Application of Hepatocyte Growth Factor - New Hope for Many Conditions

BEIJING, Dec. 2, 2013 /PRNewswire/ -- ReLife International Medical Center researches hepatocyte growth factors. HGF is a paracrine cellular growth, motility and morphogenic factor secreted by mesenchymal cells. By acting as a multi-functional cytokine, HGF is being applied in treatments for not only hepatic conditions but also many other diseases in nowadays due to its angionenic, anti-fibrotic and antiapoptosis actions. [1, 2]

Ischemic diseases  HFG can stimulate the migration, proliferation and neovascularization of vascular endothelial cells. In addition, HGF is capable of protecting the nerves cell by increasing neuronal survival and axonal regeneration. HGF has proven to be effective in gene therapy for limb ischemia conditions and myocardial ischemia. Decreasing of ulceration area and pain relief have been shown in patients with lower limb ischemia conditions after being treated with HGF. Combination of mesenchymal stem cells - MSCs with adenovirus carrying HGF can promote neovascularization in chronic ischemic myocardium, inhibit apoptosis and improve the cardiac functions.

Diabetes  HFG can inhibit the apoptosis of endothelial cells under hyperglycemic environment and promote the repair process of vascular endothelial cells, which is an ideal treatment for diabetic vascular complications. On the other hand, HGF can inhibit the fibrosis of renal interstitium of Diabetic Nephropathy. It can also promote MSCs to differentiate into islet cells in stem cell therapy.

Others  HFG is able to relieve neuron hypoxia injuries and promote neural stem cells to differentiate into neuronal cells. HGF can also protect human pulmonary microvascular endothelial cells and promote the repair of damage resulting from a pulmonary injury, etc.

With its multi-functional characteristics, HGF might have a bright future in the medical field.

[1] Azuma J, Taniyama Y, Takeya Y, et al. Angiogenic and antifibrotic actions of hepatocyte growth factor improve cardiac dysfunction in porcine ischemic cardiomyopathy. Gene Ther, 2006, 13: 1206--1213

[2] Jayasankar V, Woo Y J, Pirolli T J, et al. Induction of angiogenesis and inhibition of apoptosis by hepatocyte growth factor effectively treats postischemic heart failure. J Card Surg, 2005, 20: 93--101

SOURCE ReLife International Medical Center



RELATED LINKS
http://relifemed.com/
http://relifemed.com/gene-therapy-2

More by this Source


Custom Packages

Browse our custom packages or build your own to meet your unique communications needs.

Start today.

 

PR Newswire Membership

Fill out a PR Newswire membership form or contact us at (888) 776-0942.

Learn about PR Newswire services

Request more information about PR Newswire products and services or call us at (888) 776-0942.